Explore the vast range of titles available.

Linear infrastructures, such as railways, tunnels, and pipelines, play essential roles in economic and social development worldwide. However, under the influence of geohazards, earthquakes, and human activities, linear infrastructures face the potential risk of damage and may not function properly. Current monitoring systems for linear infrastructures are mainly based on non-contact detection (InSAR, UAV, GNSS, etc.) and geotechnical instrumentation (extensometers, inclinometers, tiltmeters, piezometers, etc.) techniques. Regarding monitoring sensitivity, frequency, and coverage, most of these methods have some shortcomings, which make it difficult to perform the accurate, real-time, and comprehensive monitoring of linear infrastructures. Distributed acoustic sensing (DAS) is an emerging sensing technology that has rapidly developed in recent years. Due to its unique advantages in long-distance, high-density, and real-time monitoring, DAS arrays have shown broad application prospects in many fields, such as oil and gas exploration, seismic observation, and subsurface imaging. In the field of linear infrastructure monitoring, DAS has gradually attracted the attention of researchers and practitioners. In this paper, recent research and the development activities of applying DAS to monitor different types of linear infrastructures are critically reviewed. The sensing principles are briefly introduced, as well as the main features. This is followed by a summary of recent case studies and some critical problems associated with the implementation of DAS monitoring systems in the field. Finally, the challenges and future trends of this research area are presented.

In recent years, natural and anthropogenic geohazards have occured frequently all over the world, and field monitoring is becoming an increasingly important task to mitigate these risks. However, conventional geotechnical instrumentations for monitoring geohazards have a number of weaknesses, such as low accuracy, poor durability, and high sensitivity to environmental interferences. In this aspect, fiber Bragg grating (FBG), as a popular fiber optic sensing technology, has gained an explosive amount of attention. Based on this technology, quasi-distributed sensing systems have been established to perform real-time monitoring and early warning of landslides, debris flows, land subsidence, earth fissures and so on. In this paper, the recent research and development activities of applying FBG systems to monitor different types of geohazards, especially those triggered by human activities, are critically reviewed. The working principles of newly developed FBG sensors are briefly introduced, and their features are summarized. This is followed by a discussion of recent case studies and lessons learned, and some critical problems associated with field implementation of FBG-based monitoring systems. Finally the challenges and future trends in this research area are presented.

Intravenous arsenic trioxide plus all-trans retinoic acid (ATRA) without chemotherapy is the standard of care for non-high-risk acute promyelocytic leukaemia (white blood cell count ≤10 × 109 per L), resulting in cure in more than 95% of cases. However, a pilot study of treatment with oral arsenic realgar-Indigo naturalis formula (RIF) plus ATRA without chemotherapy, which has a more convenient route of administration than the standard intravenous regimen, showed high efficacy. In this study, we compare an oral RIF plus ATRA treatment regimen with the standard intravenous arsenic trioxide plus ATRA treatment regimen in patients with non-high-risk acute promyelocytic leukaemia. We did a multicentre, non-inferiority, open-label, randomised, controlled phase 3 trial at 14 centres in China. Patients aged 18–70 years with newly diagnosed (within 7 days) non-high-risk acute promyelocytic leukaemia, and a WHO performance status of 2 or less were eligible. Patients were randomly assigned (2:1) to receive treatment with RIF-ATRA or arsenic trioxide-ATRA as the induction and consolidation therapy. Randomisation was done centrally with permuted blocks and stratification according to trial centre and was implemented through an interactive web response system. RIF (60 mg/kg bodyweight daily in an oral divided dose) or arsenic trioxide (0·15 mg/kg daily in an intravenous dose) and ATRA (25 mg/m2 daily in an oral divided dose) were used until complete remission was achieved. The home-based consolidation therapy was RIF (60 mg/kg daily in an oral divided dose) or intravenous arsenic trioxide (0·15 mg/kg daily in an intravenous dose) in a 4-week on 4-week off regimen for four cycles and ATRA (25 mg/m2 daily in an oral divided dose) in a 2-week on 2-week off regimen for seven cycles. Patients and treating physicians were not masked to treatment allocation. The primary outcome was event-free survival at 2 years. A non-inferiority margin of −10% was used to assess non-inferiority. Primary analyses were done in a modified intention-to-treat population of all patients who received at least one dose of their assigned treatment and the per-protocol population. This study was registered with the Chinese Clinical Trial Registry (ChiCTR-TRC-13004054), and the trial is complete. Between Feb 13, 2014, and Aug 31, 2015, 109 patients were enrolled and assigned to RIF-ATRA (n=72) or arsenic trioxide-ATRA (n=37). Three patients in the RIF-ATRA and one in the arsenic trioxide-ATRA did not receive their assigned treatment. After a median follow-up of 32 months (IQR 27–36), 67 (97%) of 69 patients in the RIF-ATRA group and 34 (94%) of 36 in the arsenic trioxide-ATRA group had achieved 2-year event-free survival in the modified intention-to-treat population. The percentage difference in event-free survival was 2·7% (95% CI, −5·8 to 11·1). The lower limit of the 95% CI for the difference in event-free survival was greater than the −10% non-inferiority margin, confirming non-inferiority (p=0·0017). Non-inferiority was also confirmed in the per-protocol population. During induction therapy, grade 3–4 hepatic toxic effects (ie, increased liver aspartate aminotransferase or alanine transaminase concentrations) were reported in six (9%) of 69 patients in the RIF-ATRA group versus five (14%) of 36 patients in the arsenic trioxide-ATRA group; grade 3–4 infection was reported in 15 (23%) of 64 versus 15 (42%) of 36 patients. Two patients in the arsenic trioxide-ATRA group died during induction therapy (one from haemorrhage and one from thrombocytopenia). Oral RIF plus ATRA is not inferior to intravenous arsenic trioxide plus ATRA for the treatment of patients with non-high-risk acute promyelocytic leukaemia. This study suggests that a completely oral, chemotherapy-free model might be an alternative to the standard intravenous treatment for patients with non-high-risk acute promyelocytic leukaemia. Foundation for innovative research group of the National Natural Science Foundation of China, the Beijing Municipal Science and Technology Commission, the National Key R&D Program of China, and the National Natural Science Foundation of China.

In the article, we present the best possible parameters α1, β1, α2, β2 ∈ ℝ and α3, β3 ∈ [1/2, 1] such that the double inequalitiesα1C(a,b)+(1−α1)A(a,b) 0 with a ≠ b, and provide new bounds for the complete elliptic integral of the second kind, where A(a, b) = (a + b)/2 is the arithmetic mean, Q(a,b)=a2+b2/2$\\begin{array}{}\\displaystyleQ(a, b)=\\sqrt{\\left(a^{2}+b^{2}\\right)/2}\\end{array}$ is the quadratic mean, C(a, b) = (a2 + b2)/(a + b) is the contra-harmonic mean, C(p; a, b) = C[pa + (1 – p)b, pb + (1 – p)a] is the one-parameter contra-harmonic mean and T3(a,b)=(2π∫0π/2a3cos2⁡θ+b3sin2⁡θdθ)2/3$\\begin{array}{}T_{3}(a,b)=\\Big(\\frac{2}{\\pi}\\int\\limits_{0}^{\\pi/2}\\sqrt{a^{3}\\cos^{2}\\theta+b^{3}\\sin^{2}\\theta}\\text{d}\\theta\\Big)^{2/3}\\end{array}$ is the Toader mean of order 3.

Degrader therapies have garnered significant attention for their innovative approach to targeting and eliminating malignancy-associated proteins, holding promise for improving outcomes for patients with relapsed or refractory (R/R) hematological malignancies, especially in cases of leukemia, non-Hodgkin lymphoma, and multiple myeloma. Currently, the main categories developed based on degraders include molecular glue (such as Cemsidomide, NX-5948), PROTACs (such as BGB-16673, AC-676, KT-333 ), and RNA degraders (such as SKY-1214). This correspondence summarizes the preclinical and clinical updates on degrader therapies presented at the ASH 2024 annual meeting.

Tumor-associated myeloid cells maintain immunosuppressive microenvironments within tumors. Identification of myeloid-specific receptors to modulate tumor-associated macrophage and myeloid-derived suppressor cell (MDSC) functions remains challenging. The leukocyte immunoglobulin-like receptor B (LILRB) family members are negative regulators of myeloid cell activation. We investigated how LILRB targeting could modulate tumor-associated myeloid cell function. LILRB2 antagonism inhibited receptor-mediated activation of SHP1/2 and enhanced proinflammatory responses. LILRB2 antagonism also inhibited AKT and STAT6 activation in the presence of M-CSF and IL-4. Transcriptome analysis revealed that LILRB2 antagonism altered genes involved in cell cytoskeleton remodeling, lipid/cholesterol metabolism, and endosomal sorting pathways, as well as changed differentiation gene networks associated with inflammatory myeloid cells as opposed to their alternatively activated phenotype. LILRB2 blockade effectively suppressed granulocytic MDSC and Treg infiltration and significantly promoted in vivo antitumor effects of T cell immune checkpoint inhibitors. Furthermore, LILRB2 blockade polarized tumor-infiltrating myeloid cells from non-small cell lung carcinoma tumor tissues toward an inflammatory phenotype. Our studies suggest that LILRB2 can potentially act as a myeloid immune checkpoint by reprogramming tumor-associated myeloid cells and provoking antitumor immunity.

Solid polymer electrolytes (SPEs) and hydrogel electrolytes were developed as electrolytes for zinc ion batteries (ZIBs). Hydrogels can retain water molecules and provide high ionic conductivities; however, they contain many free water molecules, inevitably causing side reactions on the zinc anode. SPEs can enhance the stability of anodes, but they typically possess low ionic conductivities and result in high impedance. Here, we develop a lean water hydrogel electrolyte, aiming to balance ion transfer, anode stability, electrochemical stability window and resistance. This hydrogel is equipped with a molecular lubrication mechanism to ensure fast ion transportation. Additionally, this design leads to a widened electrochemical stability window and highly reversible zinc plating/ stripping. The full cell shows excellent cycling stability and capacity retentions at high and low current rates, respectively. Moreover, superior adhesion ability can be achieved, meeting the needs of flexible devices. Excess water in hydrogel-based zinc ion batteries causes side reactions, but reduced water content results in low conductivities. Here, authors develop a lean-water hydrogel based on molecular lubrication mechanism for fast ion transportation, extended stability, and reversible Zinc plating/stripping.

A 19-year-old man presented with a 10-day history of rapidly worsening acne, along with fever, muscle aches, and knee pain. Diffuse papulonodular and pustular lesions were noted on physical examination.